Metagenomi Therapeutics, Inc. (MGX)
0.92
-0.10
(-9.80%)
USD |
NASDAQ |
Oct 13, 14:53
Metagenomi Therapeutics Total Liabilities (Quarterly) : 61.13M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.13M |
| March 31, 2026 | 59.17M |
| December 31, 2025 | 74.68M |
| September 30, 2025 | 69.49M |
| June 30, 2025 | 76.45M |
| March 31, 2025 | 85.21M |
| December 31, 2024 | 89.74M |
| September 30, 2024 | 102.58M |
| Date | Value |
|---|---|
| June 30, 2024 | 116.49M |
| March 31, 2024 | 139.77M |
| December 31, 2023 | 149.67M |
| September 30, 2023 | 154.70M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 142.81M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 173.70M |
| Shareholders Equity (Quarterly) | 112.57M |
| Debt to Equity Ratio | 0.3351 |
| Current Ratio | 4.504 |
| Net Debt Paydown Yield | 2.99% |